Keyphrases
Tumor
69%
Overall Survival
61%
Chemotherapy
51%
Phase II Study
50%
Non-small Cell Lung Cancer (NSCLC)
48%
Progression-free Survival
42%
Breast Cancer
41%
Phase II Trial
40%
Confidence Interval
40%
Relapsed or Refractory
31%
Clinical Trials
28%
Rituximab
27%
Lung Cancer
24%
Mantle Cell Lymphoma
22%
Metastatic Breast Cancer
21%
Hazard Ratio
21%
Targeted Therapy
21%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
20%
Doxorubicin
20%
Follicular Lymphoma
19%
Diffuse Large B-cell Lymphoma (DLBCL)
19%
Radiation Therapy
19%
Brentuximab Vedotin
18%
In Cancer
18%
Adverse Events
18%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
17%
Cisplatin
17%
Gemcitabine
17%
Triple-negative Breast Cancer
16%
Complete Response
16%
Partial Response
15%
Programmed Death-ligand 1 (PD-L1)
15%
NCCN Guidelines
15%
Docetaxel
15%
Oncology
15%
Clinical Outcomes
15%
Pancreatic Cancer
15%
Overall Response Rate
15%
Hodgkin Lymphoma
14%
Lymphoma
14%
Colorectal Cancer
14%
Carboplatin
14%
Median Overall Survival
14%
Non-Hodgkin Lymphoma
14%
Pembrolizumab
13%
T Cells
13%
Median Progression-free Survival
13%
Older Adults
13%
Solid Tumors
13%
Phase I Study
13%
Immune Checkpoint Inhibitors
13%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
13%
Circulating Tumor DNA (ctDNA)
12%
Bevacizumab
12%
Paclitaxel
12%
Placebo
12%
Cyclophosphamide
12%
Pancreatic Ductal Adenocarcinoma
12%
Melanoma
12%
Randomized Phase II Trial
12%
Previously Treated
12%
Response Rate
11%
Glioblastoma
11%
Disease Progression
11%
Sarcoma
11%
Objective Response Rate
11%
High Risk
11%
Monotherapy
11%
Stable Disease
11%
Small Cell Lung Cancer
11%
Whole Genome
11%
Neutropenia
10%
Metastasis
10%
Tumor Cells
10%
Peripheral T-cell Lymphoma
10%
Older Patients
10%
Treatment Options
10%
Maximum Tolerated Dose
10%
Chronic Lymphocytic Leukemia
10%
Pan-cancer Analysis
10%
Systemic Therapy
10%
Soft Tissue Sarcoma
10%
Prednisone
10%
Newly Diagnosed
10%
Cetuximab
10%
Tumor Microenvironment
9%
Dose Escalation
9%
Human Epidermal Growth Factor Receptor 2 (HER2)
9%
Antitumor Activity
9%
Neoadjuvant
9%
Radiotherapy
9%
Head-and-neck Cancer
9%
Malignancy
9%
Multiple Myeloma
9%
Cancer Treatment
9%
Etoposide
9%
United States
9%
Cancer Types
9%
Colorectal Liver Metastases
9%
Resection
9%
Medicine and Dentistry
Neoplasm
100%
Diseases
68%
Malignant Neoplasm
65%
Breast Cancer
62%
Overall Survival
62%
Non Small Cell Lung Cancer
42%
Progression Free Survival
41%
Clinical Trial
33%
Oncology
31%
Cancer
29%
Radiation Therapy
28%
Lung Cancer
28%
Immunotherapy
27%
Metastatic Carcinoma
25%
Rituximab
24%
Targeted Therapy
20%
Adverse Event
20%
Arm
19%
Mantle Cell Lymphoma
19%
Recurrent Disease
19%
Hodgkin's Lymphoma
19%
Surgery
18%
Biological Marker
18%
Non-Hodgkin Lymphoma
17%
Diffuse Large B-Cell Lymphoma
17%
T Cell
16%
Melanoma
16%
Hazard Ratio
16%
Connective Tissue Cancer
14%
Metastatic Breast Cancer
14%
Cisplatin
13%
Follicular Lymphoma
13%
Doxorubicin
13%
Immunity
13%
Phase II Trials
12%
Pembrolizumab
12%
Triple Negative Breast Cancer
12%
Brentuximab Vedotin
12%
Paclitaxel
12%
Prostate Cancer
12%
Colorectal Carcinoma
12%
Pancreas Cancer
11%
Small Cell Lung Cancer
11%
Transplantation
11%
Systemic Therapy
11%
Solid Malignant Neoplasm
11%
Gemcitabine
11%
Soft Tissue Sarcoma
11%
Circulating Tumor DNA
10%
Pancreas Adenocarcinoma
10%
Placebo
10%
Positron Emission Tomography
10%
Peripheral T-Cell Lymphoma
10%
Tumor Progression
10%
Cancer Cell
10%
Immune Checkpoint Inhibitor
10%
Cyclophosphamide
10%
Chemoradiotherapy
10%
Cancer Therapy
9%
Quality of Life
9%
Hormone Therapy
9%
Head and Neck Squamous Cell Carcinoma
9%
Glioblastoma
9%
Epidermal Growth Factor Receptor
8%
B Cell
8%
Carboplatin
8%
Human Immunodeficiency Virus
8%
B-Cell Chronic Lymphocytic Leukemia
8%
Tumor Cell
8%
Multiple Myeloma
8%
Classical Hodgkin Lymphoma
8%
Systematic Review
7%
Neoadjuvant Chemotherapy
7%
Disease Free Survival
7%
Colorectal Liver Metastasis
7%
Survival Rate
7%
Squamous Cell Carcinoma
7%
Bevacizumab
7%
Nivolumab
7%
Disease Exacerbation
6%
Rectum Cancer
6%
B-Cell Lymphoma
6%
Lenalidomide
6%
Adjuvant Chemotherapy
6%
Vincristine
6%
Bendamustine
6%
Prognostic Factor
6%
Ibrutinib
6%
Head and Neck Cancer
6%
Stem Cell Transplant
6%
Health Care Cost
6%
Monotherapy
6%
Cetuximab
6%
Diagnosis
6%
Hematopoietic Cell
6%
Malignant Peripheral Nerve Sheath Tumor
6%
Cohort Analysis
6%
Neutropenia
6%
Etoposide
6%
Primary Tumor
6%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
78%
Chemotherapy
65%
Diseases
59%
Malignant Neoplasm
57%
Overall Survival
56%
Progression Free Survival
47%
Non Small Cell Lung Cancer
46%
Breast Cancer
34%
Rituximab
31%
Clinical Trial
29%
Adverse Event
28%
Lung Cancer
26%
Paclitaxel
22%
Doxorubicin
21%
Nonhodgkin Lymphoma
20%
Phase II Trials
19%
Solid Malignant Neoplasm
18%
Metastatic Breast Cancer
18%
Follicular Lymphoma
17%
Diffuse Large B Cell Lymphoma
16%
Cisplatin
16%
Immunotherapy
15%
Prostate Cancer
15%
Mantle Cell Lymphoma
15%
Biological Marker
15%
Docetaxel
14%
Carboplatin
14%
Cyclophosphamide
14%
Gemcitabine
14%
Placebo
13%
Small Cell Lung Cancer
13%
Recurrent Disease
12%
Epidermal Growth Factor Receptor
12%
Hodgkin Disease
12%
Chemoradiation Therapy
11%
Bevacizumab
10%
Monotherapy
10%
Colorectal Carcinoma
10%
Pharmacokinetics
10%
Metastasis
10%
Brentuximab Vedotin
10%
Neutropenia
10%
Glioblastoma
10%
Melanoma
10%
Remission
10%
Etoposide
9%
Bendamustine
9%
Cetuximab
9%
Vincristine
9%
Pembrolizumab
9%
Head and Neck Squamous Cell Carcinoma
9%
Pancreas Cancer
9%
Maximum Tolerated Dose
9%
Prednisone
8%
Soft Tissue Sarcoma
8%
Antitumor Activity
8%
Pancreas Adenocarcinoma
8%
Triple Negative Breast Cancer
8%
Tumor Growth
8%
Disease Exacerbation
8%
Chronic Lymphatic Leukemia
8%
Survival Rate
7%
Tolerability
7%
Bortezomib
7%
Leukemia
7%
Lenalidomide
7%
Diarrhea
7%
Pemetrexed
6%
Connective Tissue Cancer
6%
Immune Checkpoint Inhibitor
6%
Thrombocytopenia
6%
Receptor
6%
Disease Free Survival
6%
Transitional Cell Carcinoma
6%
Erlotinib
6%
Endocrine Therapy
6%
Anemia
5%
Palbociclib
5%
Peripheral T Cell Lymphoma
5%
Castration Resistant Prostate Cancer
5%
Circulating Tumor DNA
5%
Squamous Cell Carcinoma
5%
Carcinogenesis
5%
Nivolumab
5%
Phosphatidylinositol 3 Kinase
5%
Estrogen Receptor
5%
Liver Cell Carcinoma
5%
Cyclin Dependent Kinase 4
5%
Combination Therapy
5%
Ibrutinib
5%
Everolimus
5%
Methotrexate
5%
Head and Neck Cancer
5%
Renal Cell Carcinoma
5%
Phase I Trials
5%
Nausea
5%
Irinotecan
5%
Febrile Neutropenia
5%
Monoclonal Antibody
5%
Temozolomide
5%